Expansion of dendritic cell precursors from human CD34+ progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome
- 1 August 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 72 (2) , 321-329
- https://doi.org/10.1189/jlb.72.2.321
Abstract
CD34(+) haematopoietic progenitor cells, which circulate at extremely low frequencies in peripheral blood, are used to generate dendritic cells (DC) in vitro. Here, we describe a method to grow large numbers of DC precursors from these low frequent cells. Different combinations of early acting haematopoietic growth factors supported expansion of CD34(+) cells. CD1a(+) DC derived from precursors, expanded in fms-like tyrosine kinase-3 ligand (Flt3-L), stem-cell factor (SCF), interleukin (IL)-3, and IL-6, were less potent antigen-presenting cells (APC) compared to CD1a(+) DC derived from precursors expanded in Flt3-L, trombopoietine (TPO), and SCF. Furthermore, the latter produced high levels of IL-12 and low levels of IL-10, a cytokine profile favorable for the priming cytotoxic T cells. In contrast, a mean increase of total cell number of 453-fold was obtained with Flt3-L, SCF, IL-3, and IL-6, and this increase was only 38-fold with Flt3-L, TPO, and SCF. Sequential cultures of both cocktails resulted in high numbers of potent APC, which can be useful DC-based cancer vaccines.Keywords
Funding Information
- Monique Monné-van Muijnen
This publication has 34 references indexed in Scilit:
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- Early progenitor cells from human mobilized peripheral blood express low levels of the flt3 receptor, but exhibit various biological responses to flt3-LBritish Journal of Haematology, 1999
- The concept of type 1 and type 2 antigen-presenting cellsImmunology Letters, 1999
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- Genetically modified bone marrow‐derived dendritic cells expressing tumor‐associated viral or “self” antigens induce antitumor immunity in vivoEuropean Journal of Immunology, 1997
- Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.The Journal of Experimental Medicine, 1996
- Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunityNature Medicine, 1995
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991
- Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1987